Related Experiment Video
Updated: Jul 9, 2025

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
Published on: March 17, 2023
Acute In Vivo Administration of Compound 21 Stimulates Akt and ERK1/2 Phosphorylation in Mouse Heart and Adipose
Diego T Quiroga1, Jorge A Narvaéz Pardo1, María G Zubiría2
1Facultad de Farmacia y Bioquímica, Departamento de Química Biológica and IQUIFIB (UBA-CONICET), Universidad de Buenos Aires, Buenos Aires C1113AAD, Argentina.
Abstract:
The angiotensin II type 2 (AT2) receptor has a role in promoting insulin sensitivity. However, the mechanisms underlying the AT2 receptor-induced facilitation of insulin are still not completely understood. Therefore, we investigated whether acute in vivo administration of AT2 receptor agonist compound 21 (C21) could activate insulin signaling molecules in insulin-target tissues. We report that, in male C57BL/6 mice, an acute (5 min, 0.25 mg/kg; i.v.) injection of C21 induces the phosphorylation of Akt and ERK1/2 at activating residues (Ser473 and Thr202/Tyr204, respectively) in both epididymal white adipose tissue (WAT) and heart tissue. In WAT, the extent of phosphorylation (p) of Akt and ERK1/2 induced by C21 was approximately 65% of the level detected after a bolus injection of a dose of insulin known to induce maximal activation of the insulin receptor (IR). In the heart, C21 stimulated p-Akt to a lesser extent than in WAT and stimulated p-ERK1/2 to similar levels to those attained by insulin administration. C21 did not modify p-IR levels in either tissue. We conclude that in vivo injection of the AT2 receptor agonist C21 activates Akt and ERK1/2 through a mechanism that does not involve the IR, indicating the participation of these enzymes in AT2R-mediated signaling.
Insights
The angiotensin II type 2 (AT2) receptor agonist C21 activates key insulin signaling molecules Akt and ERK1/2 in mice. This activation occurs independently of the insulin receptor (IR), suggesting novel pathways for improved insulin sensitivity.
Area of Science:
- Endocrinology
- Molecular Biology
- Cardiovascular Research
Background:
- The angiotensin II type 2 (AT2) receptor is implicated in enhancing insulin sensitivity.
- The precise molecular mechanisms of AT2 receptor-mediated insulin facilitation remain unclear.
Purpose of the Study:
- To determine if acute in vivo administration of the AT2 receptor agonist C21 activates insulin signaling pathways in target tissues.
- To elucidate the role of the insulin receptor (IR) in AT2 receptor-induced signaling.
Main Methods:
- Acute intravenous injection of C21 (0.25 mg/kg) in male C57BL/6 mice.
- Analysis of Akt and ERK1/2 phosphorylation in epididymal white adipose tissue (WAT) and heart tissue.
- Assessment of insulin receptor (IR) phosphorylation levels.
Main Results:
- C21 induced significant phosphorylation of Akt and ERK1/2 in both WAT and heart.
- C21-mediated phosphorylation of Akt and ERK1/2 in WAT was substantial, reaching ~65% of insulin-induced levels.
- C21 stimulated p-Akt in the heart to a lesser extent than in WAT, and p-ERK1/2 to levels comparable to insulin.
- Crucially, C21 did not alter insulin receptor (IR) phosphorylation in either tissue.
Conclusions:
- Acute in vivo administration of the AT2 receptor agonist C21 activates Akt and ERK1/2 signaling.
- This activation proceeds through a mechanism independent of the insulin receptor (IR).
- These findings highlight the involvement of Akt and ERK1/2 in AT2 receptor-mediated signaling pathways relevant to insulin sensitivity.
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
GPCRs Regulate Adenylyl Cylase Activity

